Category : Search result: Ozempic alternative


Private Credit AIFs: India's Steady Return Haven

As global markets swing, investors seek stable, risk-adjusted returns. Discover how India's private credit AIFs, now a $20.6 billion market, provide a resilient alternative linked to the real economy.

Sebi May Let AIFs Certify Accredited Investors Soon

Sebi's top committee is close to deciding if AIFs can certify accredited investors, easing a cumbersome process. This move, inspired by GIFT City, could boost investor participation in high-risk funds. Read the latest developments.

New Spherical Cap Studs Reduce Ride Discomfort by 45%

Researchers from NIT Silchar and Nirma University create Spherical Cap Studs, a new speed control solution that cuts discomfort by 45.57% while maintaining safety. Read about this DST-funded innovation.

WHO's First Guidelines on GLP-1 Drugs for Obesity

WHO releases first-ever global guidelines for GLP-1 medicines to treat obesity, a chronic disease. Learn about the key recommendations and new mental health warnings from Australia.

PFRDA's New NPS Platform to Channel Pension Funds into AIFs

PFRDA chairman S Ramann announces a dedicated NPS fund-of-funds platform to route pension money into AIFs, aiming to provide stable, long-term capital for India's private markets. Discover how this move will reshape domestic capital formation.

5 Winter Foods That Mimic Ozempic Naturally

Discover 5 winter foods that naturally mimic Ozempic effects for weight loss and blood sugar control. Scientific study reveals natural alternatives to weight loss drugs with fewer side effects.

India's Accredited Investor Count Stalls at 649

Sebi's push for accredited investors sees modest registration. With only 649 AIs, the industry debates if new rules can unlock growth in high-risk alternative investments. Explore the challenges and opportunities.

Medicare Cuts Prices for Ozempic, Cancer Drugs

US government announces major Medicare price reductions for 15 prescription drugs including Ozempic, Wegovy and cancer treatments. Savings expected from 2027. Read more.

Salesforce CEO Switches from ChatGPT to Google Gemini

Salesforce CEO Marc Benioff declares he'll never use ChatGPT again after experiencing Google's Gemini 3.0, calling it an 'insane leap' in AI capability. Read the full story about this major shift in enterprise AI preferences.

Page 1 of 4